Boston Scientific shares have moved higher following promising clinical results and reports of insider buying, even as the company was dropped from several Russell growth benchmarks including the Russell 1000 Growth and Russell 3000 Growth indices. The stock recently traded at $44.60, with a 30-day return down 8.14% and a 90-day return down 27.90%, while the one-year total shareholder return is down 57.05%. Analysts have highlighted slower growth in the Watchman device franchise and trimmed expectations, though a popular valuation narrative on Simply Wall St pegs fair value at $98.90 per share, suggesting the stock is significantly undervalued. The long-term outlook remains bullish among some analysts, driven by expectations that higher-growth segments will account for 60% of revenue by 2028.
Boston Scientific CorpPromising clinical results drove shares higher